Partner and funding
What is Target Late AMD?
Our two first projects were designed to treat rather early stages of AMD before cell loss has been occurred. This third project aimed at treating advanced stages of AMD.
Our goal with Target Late AMD
Goals
The gene therapy approach based on Target AMD 1.0, consist in the transplantation of a patient’s own iris pigment epithelial (IPE) cells genetically modified to overexpress therapeutic genes aiming at recovering a healthy retinal environment, stopping vessel growth (in wet AMD), or reducing inflammation and oxidative stress (in dry AMD).
What is Target Late AMD?
Project status/Results
Target Late AMD started in November 2022. The current project will be completed in April 2024 and focus on the establishment of the production of the cell product, i.e., retinal pigment epithelial (RPE) cells derived from autologous induced pluripotent stem cells (iPSC) and genetically modified (transfected) to produce therapeutic factors (PEDF and GM-CSF) aiming at recovering a healthy retinal environment.
